Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Promise-O2
NCT04808401Recruiting
- Sponsor
- Insel Gruppe
- Start
- May 2021
- Primary completion
- Dec 2027
- Modality
- Inhalation Devices
- Countries
- 1
01
Overview
Randomised, open-label trial of oxygen in coronary artery disease (CAD) (4 arms), sponsored by Insel Gruppe. Primary endpoint: High-sensitive Troponin T. Started May 2021; status: recruiting.
02
Drugs
oxygen
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT04808401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04808401.